Department of Medical Oncology, Longhua Hospital, Shanghai, China.
Integr Cancer Ther. 2011 Jun;10(2):127-37. doi: 10.1177/1534735410387599. Epub 2010 Dec 8.
Targeted therapy (TT), chemotherapy, and traditional Chinese medicine herbal treatment (TCM) can improve the prognosis of advanced pulmonary adenocarcinoma patients. Their independent prognostic value is unknown.
To study whether TCM improves survival in stage IV pulmonary adenocarcinoma patients with platinum-based chemotherapy (PBT), or combined PBT and second-line TT.
Retrospective analysis of 133 fully ambulant clinical outpatients treated with PBT alone or PBT with/without second-line TT, with/without TCM. Univariate (Kaplan-Meier) and multivariable (Cox model) survival analysis were performed, using disease-specific mortality as an endpoint.
Gender (P = .002), TT (P < .0001), and TCM (P < .0001) had univariate prognostic value but not age, radiotherapy, or TCM syndrome differentiation (P > .10). TCM herbal treatment (P < .0001) and TT (P = .03) had multivariable independent prognostic value. TCM-treated patients (n = 103, PBT+TT+TCM+ = 62; PBT+TT-TCM+ =41) had 88% 1-year overall survival rate with median survival time (MST) of 27 months, contrasting 27% 1-year overall survival and MST of 5.0 months for non-TCM-treated (n = 30) patients. Patients with chemotherapy/TT/TCM (PBT+TT+TCM+, n = 62), TCM without TT (PBT+TT-TCM+, n = 41), or chemotherapy only (PBT+TT-TCM-, n = 30), had 1-year survival rates of 94%, 78%, and 27% respectively; for these 3 groups, respectively, MST was not reached (MST of 30.9 months), 22.6, and 5.0 months (P < .0001).
TCM herbal treatment may improve survival of stage IV pulmonary adenocarcinoma patients treated with chemotherapy without or with second-line TT. This warrants formal phase 1 and 2 trials and ultimately properly designed prospective clinical validation trials with adequate methodology developed for data collection.
靶向治疗(TT)、化疗和中药治疗(TCM)可改善晚期肺腺癌患者的预后。但它们各自的预后价值尚不清楚。
研究 TCM 是否可改善接受铂类化疗(PBT)、PBT 联合二线 TT 治疗的 IV 期肺腺癌患者的生存。
回顾性分析 133 例接受单纯 PBT 或 PBT 联合/不联合二线 TT 及 TCM 治疗的完全可走动的门诊患者。采用单变量(Kaplan-Meier)和多变量(Cox 模型)生存分析,以疾病特异性死亡率为终点。
性别(P =.002)、TT(P <.0001)和 TCM(P <.0001)有单变量预后价值,但年龄、放疗和 TCM 辨证(P >.10)无此作用。TCM 治疗(P <.0001)和 TT(P =.03)有独立的多变量预后价值。接受 TCM 治疗的患者(n = 103,PBT+TT+TCM+ = 62;PBT+TT-TCM+ = 41)的 1 年总生存率为 88%,中位生存时间(MST)为 27 个月,而未接受 TCM 治疗的患者(n = 30)的 1 年总生存率为 27%,MST 为 5.0 个月(P <.0001)。接受化疗/TT/TCM(PBT+TT+TCM+,n = 62)、仅化疗/TT(PBT+TT-TCM+,n = 41)和仅化疗(PBT+TT-TCM-,n = 30)的患者的 1 年生存率分别为 94%、78%和 27%,MST 分别为未达到(MST 为 30.9 个月)、22.6 和 5.0 个月(P <.0001)。
TCM 治疗可能改善接受化疗、无论是否接受二线 TT 治疗的 IV 期肺腺癌患者的生存。这需要进行正式的 1 期和 2 期试验,并最终开发适当的前瞻性临床试验,采用适当的方法进行数据收集进行前瞻性验证。